WEREWOLF THERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Basic
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Net Income (Loss) Available to Common Stockholders, Basic of -$13.53 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$13.53M.
- WEREWOLF THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$8.38M.
- WEREWOLF THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$16.37M.
- WEREWOLF THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-06-30 was -$17.98M.
- WEREWOLF THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was -$37.37M.
- WEREWOLF THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2022 was -$53.81M.
- WEREWOLF THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2021 was -$201.93M.
- WEREWOLF THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2020 was -$28.22M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$13.53M 10-Q · filed 2026-05-07 | -$21.91M derived: sum of 2 quarters · filed 2026-09-22 | -$38.28M derived: sum of 3 quarters · filed 2026-09-22 | -$56.27M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-12-31 | -$8.38M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | -$24.75M derived: sum of 2 quarters · filed 2026-09-22 | -$42.73M derived: sum of 3 quarters · filed 2026-09-22 | -$60.82M S-4 · filed 2026-09-22 |
| 2025-09-30 | -$16.37M 10-Q · filed 2025-11-04 | -$34.35M derived: sum of 2 quarters · filed 2025-11-04 | -$52.44M 10-Q · filed 2025-11-04 | -$72.84M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-06-30 | -$17.98M 10-Q · filed 2025-08-14 | -$36.07M 10-Q · filed 2025-08-14 | -$56.47M derived: sum of 3 quarters · filed 2026-09-22 | -$73.14M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-03-31 | -$18.09M 10-Q · filed 2026-05-07 | -$38.49M derived: sum of 2 quarters · filed 2026-09-22 | -$55.16M derived: sum of 3 quarters · filed 2026-09-22 | -$72.41M derived: sum of 4 quarters · filed 2026-09-22 |
| 2024-12-31 | -$20.40M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | -$37.07M derived: sum of 2 quarters · filed 2026-09-22 | -$54.32M derived: sum of 3 quarters · filed 2026-09-22 | -$70.52M S-4 · filed 2026-09-22 |
| 2024-09-30 | -$16.67M 10-Q · filed 2025-11-04 | -$33.92M derived: sum of 2 quarters · filed 2025-11-04 | -$50.12M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | -$17.25M 10-Q · filed 2025-08-14 | -$33.44M 10-Q · filed 2025-08-14 | ||
| 2023-12-31 | -$12.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$20.29M derived: sum of 2 quarters · filed 2025-03-11 | -$25.39M derived: sum of 3 quarters · filed 2025-03-11 | -$37.37M 10-K · filed 2025-03-11 |
| 2023-09-30 | -$8.29M 10-Q · filed 2024-11-07 | -$13.38M derived: sum of 2 quarters · filed 2024-11-07 | -$25.36M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$5.10M 10-Q · filed 2024-08-08 | -$17.08M 10-Q · filed 2024-08-08 | ||
| 2022-12-31 | -$11.93M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$23.87M derived: sum of 2 quarters · filed 2023-03-23 | -$38.47M derived: sum of 3 quarters · filed 2023-03-23 | -$53.81M 10-K · filed 2023-03-23 |
| 2022-09-30 | -$11.94M 10-Q · filed 2022-11-10 | -$26.54M derived: sum of 2 quarters · filed 2022-11-10 | -$41.88M 10-Q · filed 2022-11-10 | -$59.75M derived: sum of 4 quarters · filed 2023-03-23 |
| 2022-06-30 | -$14.59M 10-Q · filed 2022-08-11 | -$29.94M 10-Q · filed 2022-08-11 | -$47.81M derived: sum of 3 quarters · filed 2023-03-23 | -$61.56M derived: sum of 4 quarters · filed 2023-03-23 |
| 2022-03-31 | -$15.34M 10-Q · filed 2022-05-10 | -$33.21M derived: sum of 2 quarters · filed 2023-03-23 | -$46.97M derived: sum of 3 quarters · filed 2023-03-23 | -$114.82M derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-12-31 | -$17.87M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$31.63M derived: sum of 2 quarters · filed 2023-03-23 | -$99.47M derived: sum of 3 quarters · filed 2023-03-23 | -$201.93M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$13.76M 10-Q · filed 2022-11-10 | -$81.61M derived: sum of 2 quarters · filed 2022-11-10 | -$184.06M 10-Q · filed 2022-11-10 | -$204.60M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$67.85M 10-Q · filed 2022-08-11 | -$170.30M 10-Q · filed 2022-08-11 | -$190.85M derived: sum of 3 quarters · filed 2022-08-11 | -$196.91M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$102.45M 10-Q · filed 2022-05-10 | -$123.00M derived: sum of 2 quarters · filed 2022-05-10 | -$129.07M derived: sum of 3 quarters · filed 2022-05-10 | -$126.84M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$20.55M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | -$26.62M derived: sum of 2 quarters · filed 2022-03-24 | -$24.39M derived: sum of 3 quarters · filed 2022-03-24 | -$28.22M 10-K · filed 2022-03-24 |
| 2020-09-30 | -$6.07M 10-Q · filed 2021-11-10 | -$3.84M derived: sum of 2 quarters · filed 2021-11-10 | -$7.67M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $2.23M 10-Q · filed 2021-08-12 | -$1.60M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$3.83M 10-Q · filed 2021-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |